NCT04672928View on ClinicalTrials.gov

A Phase Ib/III Clinical Study to Evaluate the Efficacy and Safety of IBI318 in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel in Patients With Small Cell Lung Cancer Who Have Failed First-line or Above Chemotherapies

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 14, 2020

Primary Completion Date

January 31, 2023

Study Completion Date

January 31, 2023

Conditions
Small Cell Lung Carcinoma
Interventions
DRUG

paclitaxel

80mg/m\^2,iv,Q4W

DRUG

IBI318

300mg,iv,Q4W

Trial Locations (1)

Unknown

Jilin Povince Cancer Hospital, Changchun

All Listed Sponsors
lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT04672928 - A Phase Ib/III Clinical Study to Evaluate the Efficacy and Safety of IBI318 in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel in Patients With Small Cell Lung Cancer Who Have Failed First-line or Above Chemotherapies | Biotech Hunter | Biotech Hunter